ClinicalTrials.gov
public full text
Public Domain
Study of DM5167 in Patients With Advanced Solid Tumors
DM5167 is a second-generation of PARP inhibitor that selectively targets the PARP-1 enzyme. This results in less haematological toxicity and a high level of safety. The aim of the study is to assess the safety and tolerability of DM5167 in patients with advanced solid tumors not respond to other treatments.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors#1009079
- A Study of HS-20122 in Patients With Advanced Solid Tumors#1057446
- PARPi and Ovarian Cancer Survival#839174
- A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b#806970
- Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors#967192
Record · ID 1093553
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive